Übersichten zu Rituximab und zur B-Zell-Depletion
Edwards JC, Leandro MJ, Cambridge G., Centre for Rheumatology, Arthur Stanley House, University College London, 40-50 Tottenham Street, London W1T 4NJ, UK., jo.edwards(at)ucl.ac.uk: B lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheum Dis Clin North Am. 2004 May;30(2):393-403, viii
Edwards JC, Leandro MJ, Cambridge G., Centre for Rheumatology, University College London, Arthur Stanley House, 40-50 Tottenham Street, London W1T 4NJ, UK., jo.edwards(at)ucl.ac.uk: B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders. Biochem Soc Trans. 2002 Aug;30(4):824-8.
Clark EA, Ledbetter JA, Department of Immunology and National Primate Research Center, Box 357330, University of Washington, Seattle, WA 98195, USA, eclark(at)bart.rprc.washington.edu: How does B cell depletion therapy work, and how can it be improved? Ann Rheum Dis. 2005 Nov;64 Suppl 4:iv77-80.
Looney RJ, Anolik J, Sanz I. , Department of Medicine, University of Rochester, Box 695, 601 Elmwood Avenue, Rochester, NY 14642, USA, John_Looney(at)URMC.Rochester.edu: B cells as therapeutic targets for rheumatic diseases.Curr Opin Rheumatol. 2004 May;16(3):180-5.
Looney RJ., University of Rochester, 601 Elmwood Avenue, Rm G-6454, Rochester, NY 14642, USA, john_looney(at)urmc.rochester.edu: B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis. Rheumatology (Oxford). 2005 May;44 Suppl 2:ii13-ii17.
Gorman C, Leandro M, Isenberg D., Centre for Rheumatology, The Middlesex Hospital, University College London, UK: B cell depletion in autoimmune disease. Arthritis Res Ther. 2003;5 Suppl 4:S17-21. Epub 2003 Oct 2
Kneitz C, Wilhelm M, Tony HP., Medizinische Poliklinik der Universitat Wurzburg, Germany, c.kneitz(at)medizin.uni-wuerzburg.de: Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology. 2002 Dec;206(5):519-27.
Chambers SA, Isenberg D., Centre for Rheumatology, The Middlesex Hospital, University College, London, UK: Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases. Lupus. 2005;14(3):210-4
Rastetter W, Molina A, White CA., IDEC Pharmaceuticals Corporation, 3030 Callan Road, San Diego, California 92121, USA: Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med. 2004;55:477-503
Goronzy JJ, Weyand CM., Departments of Medicine and Immunology, Mayo Clinic, Rochester, MN, USA, goronzy.jorg(at)mayo.edu: B cells as a therapeutic target in autoimmune disease. Arthritis Res Ther. 2003;5(3):131-5. Epub 2003 Mar 19
Keystone EC, The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, The Joseph and Wolf Lebovic Building, 2nd Floor, Room 2-006, 60 Murray Street, Toronto, Ontario M5G 1X5, Canada. ksnow(at)mtsinai.on.ca: B cells in rheumatoid arthritis: from hypothesis to the clinic. Rheumatology (Oxford). 2005 May;44 Suppl 2:ii8-ii12.
Looney RJ., Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA. John_Looney(at)URMC.Rochester.Edu: B cell-targeted therapy for rheumatoid arthritis: an update on the evidence. Drugs. 2006;66(5):625-39
Brezinschek HP, Brickmann K, Yazdani-Biuki B, Dorner T, Graninger WB, Brezinschek RI.
Rheumatic Diseases Division, Department of Internal Medicine, Medical University Graz, Graz, Austria. hans-peter.brezinschek(at)meduni-graz.at: Treatment of rheumatoid arthritis in the 21st century: targeting B-lymphocytes. Wien Med Wochenschr. 2006 Jan;156(1-2):61-7
Weitere Erkrankungen
Weinreb N, Rabinowitz A, Dellaripa PF. Beneficial response to rituximab in refractory Felty Syndrome.J Clin Rheumatol. 2006 Feb;12(1):48
Bhatia A, Ell PJ, Edwards JC: Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis. 2005 Jul;64(7):1099-100.
Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, Vissink A, Kallenberg CG, Bootsma H, Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, Groningen, The Netherlands. j.pijpe(at)kchir.umcg.nl: Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum. 2005 Sep;52(9):2740-50.
Omdal R, Wildhagen K, Hansen T, Gunnarsson R, Kristoffersen G, Department of Internal Medicine, Clinical Immunology Unit, Stavanger University Hospital, Stavanger, Norway. omro(at)sir.no: Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response. Scand J Rheumatol. 2005 May-Jun;34(3):229-32.
Eriksson P., Department of Rheumatology, University Hospital, Linkoping, Sweden. per.eriksson(at)lio.se: Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med. 2005 Jun;257(6):540-8
Keogh KA, Wylam ME, Stone JH, Specks U, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA: Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.Arthritis Rheum. 2005 Jan;52(1):262-8
Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U, Division of Pulmonary and Critical Care Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA: Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med. 2006 Jan 15;173(2):180-7. Epub 2005 Oct 13
Ahmadi-Simab K, Lamprecht P, Nolle B, Ai M, Gross WL: Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis. 2005 Jul;64(7):1087-8
Kindlicher Lupus
Willems M, Haddad E, Niaudet P, Kone-Paut I, Bensman A, Cochat P, Deschenes G, Fakhouri F, Leblanc T, Llanas B, Loirat C, Pillet P, Ranchin B, Salomon R, Ulinski T, Bader-Meunier B; French Pediatric-Onset SLE Study Group, Department of Pediatrics, Hopital de Bicetre, Le Kremlin Bicetre, France. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr. 2006 May;148(5):623-627
Marks SD, Patey S, Brogan PA, Hasson N, Pilkington C, Woo P, Tullus K.
Department of Paediatric Nephrology, Institute of Child Health and Great Ormond Street Hospital for Children NHS Trust, London, UK. s.marks(at)ich.ucl.ac.uk: B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum. 2005 Oct;52(10):3168-74
Systemischer Lupus erythematodes (SLE)
Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA.
Rheumatology, Middlesex Hospital, University College, 4th Floor Arthur Stanley House, 40-50 Tottenham Street, London W1T 4NJ, UK. maria.leandro(at)ucl.ac.uk: An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002 Oct;46(10):2673-7
Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I., University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA. John_Looney(at)URMC.Rochester.edu: B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.
Arthritis Rheum. 2004 Aug;50(8):2580-9
Sfikakis PP, Boletis JN, Tsokos GC., First Department of Propedeutic and Internal Medicine, Athens University Medical School, Greece, psfikakis(at)med.uoa.gr: Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol. 2005 Sep;17(5):550-7
Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. , Centre for Rheumatology, University College London, London, UK: B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.Rheumatology (Oxford). 2005 Dec;44(12):1542-5. Epub 2005 Sep 27
Ng KP, Leandro MJ, Edwards JC, Ehrenstein MR, Cambridge G, Isenberg DA. , Centre for Rheumatology, University College London, Arthur Stanley House, 40-50 Tottenham Street, London W1T 4NJ, UK: Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis. 2006 Jul;65(7):942-5. Epub 2005 Nov 3:
Rituximab provides new hope for people with lupus. Medical Study News. Published: Thursday, 9-Jun-2005,
Rheumatoide Arthritis
Die ersten Studien:
De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G.
University of Udine, Udine, Italy. gf.ferraccioli(at)med.uniud.it: Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum. 2002 Aug;46(8):2029-33
Leandro MJ, Edwards JC, Cambridge G., Centre for Rheumatology, University College London, UK: Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion.Ann Rheum Dis. 2002 Oct;61(10):883-8
Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004 Jun 17;350(25):2572-81.
Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M, Webster AD, Centre for Rheumatology, University College London, Arthur Stanley House, 40-50 Tottenham Street, London W1T 4NJ, UK: Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 2003 Aug;48(8):2146-54
Kneitz C, Wilhelm M, Tony HP, Medizinische Poliklinik der Universitat Wurzburg, Germany. c.kneitz(at)medizin.uni-wuerzburg.de: Improvement of refractory rheumatoid arthritis after depletion of B cells.Scand J Rheumatol. 2004;33(2):82-6
DANCER-Studie:
Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54:1390-1400
Emery P, A. Filipowicz-Sosnowska, L. Szczepanski, A. Racewicz, J. Schechtman, R. M., Fleischmann, R. Van Vollenhoven, N. F. Li, S. Agarwal, E. Hessey, T. M. Shaw: PRIMARY ANALYSIS OF A DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING TRIAL OF RITUXIMAB, AN ANTI-CD20 MONOCLONAL ANTIBODY, IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING METHOTREXATE (DANCER TRIAL). EULAR 2005, Wien, OP0008
Emery P et al, EULAR 2006; OP0017
REFLEX-Studie:
Cohen SB, M. Greenwald, M. R. Dougados, P. Emery, R. Furie, T. M. Shaw, M. C. Totoritis: Efficacy and Safety of Rituximab in Active R A Patients who Experienced an Inadequate Response to one or More Anti-TNFa Therapies (REFLEX Study). ACR/ARHP Annual Scientific Meeting; November 13-16, 2005; San Diego, CA. Abstract 1830.
E. Keystone1, P. Emery2, C. G. Peterfy3, P. P. Tak4, S. Cohen5, M. Genovese6, S. Williams7, M. Totoritis8, M. Cravets8, T. Shaw7
PREVENTION OF JOINT STRUCTURAL DAMAGE AT 1 YEAR WITH RITUXIMAB IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO ONE OR MORE TNF INHIBITORS (REFLEX STUDY)
EULAR 2006: Annals of Rheumatic Diseases 2006; 65 Suppl II: 58. Abstract OP0016
J. M. Kremer1, H. Tony2, P. P. Tak3, M. Luggen4, X. Mariette5, E. Hessey6, D. McCabe7, S. Safa-Leathers6.
EFFICACY OF RITUXIMAB IN ACTIVE RA PATIENTS WITH AN INADEQUATE RESPONSE TO ONE OR MORE TNF INHIBITORS.
EULAR 2006: Annals of Rheumatic Diseases 2006; 65 Suppl II: 326. Abstract FRI0133
S. B. Cohen1, M. Greenwald2, M. Dougados3, P. Emery4, R. Furie5, T. Shaw6, M. Totoritis7
EFFICACY AND SAFETY OF RITUXIMAB IN ACTIVE RA PATIENTS WHO EXPERIENCED INADEQUATE RESPONSES TO ONE OR MORE TNF INHIBITORS
EULAR 2006: Annals of Rheumatic Diseases 2006; 65 Suppl II: 108-109. Abstract OP0179
S. Cohen1, P. Emery2, M. Greenwald3, M. Dougados4, R. Furie5, G. Burmester6, S. Williams7, M. Cravets8, F. Magrini7
PROLONGED EFFICACY OF RITUXIMAB IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO ONE OR MORE TNF INHIBITORS: 1-YEAR FOLLOW-UP OF A SUBSET OF PATIENTS RECEIVING A SINGLE COURSE IN A CONTROLLED TRIAL (REFLEX STUDY)
EULAR 2006: Annals of Rheumatic Diseases 2006; 65 Suppl II: 183. Abstract THU0220
G. R. Burmester1, E. M. Ruderman2, P. Durez3, J. Loveless4, T. K. Kvien5, C. Jackson6, L. Burke7, M. Cravets8, A. M. White7
Oral glucocorticoids have no impact on the efficacy or safety profile of rituximab in rheumatoid arthritis patients with inadequate response to TNF inhibitors (REFLEX study)
EULAR 2006: Annals of Rheumatic Diseases 2006; 65 Suppl II: 180. Abstract THU0211
Verträglichkeit und Therapiesicherheit:
Higashida J et al: Safety and Efficacy of Rituximab in Patients with Rheumatoid Arthritis Refractory to Disease Modifying Antirheumatic Drugs and Anti-Tumor Necrosis Factor-alpha-Treatment. J Rheumatol 2005;32:2109-15
Kimby E: Tolerability and safety of rituximab (MabThera®). Cancer Treatment Reviews
Volume 31, Issue 6 , October 2005, Pages 456-473
Kavanaugh AF, Center for Innovative Therapy, University of California San Diego, San Diego, California 92093-0943, USA. akavanaugh(at)ucsd.edu: B cell targeted therapies: safety considerations. J Rheumatol Suppl. 2006 May;77:18-23
Hainsworth JD., Sarah Cannon Cancer Center, Nashville, Tennessee, USA. jhainsworth(at)tnonc.com: Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis. Arthritis Res Ther. 2003;5 Suppl 4:S12-6. Epub 2003 Dec 2
Wirkmechanismus:
Szodoray P, Alex P, Dandapani V, Nakken B, Pesina J, Kim X, Wallis GL, Wilson PC, Jonsson R, Centola M., Broegelmann Research Laboratory, The Gade Institute, University of Bergen, Armauer Hansen Building, N-5021 Bergen, Norway, peter.szodoray(at)gades.uib.no: Apoptotic effect of rituximab on peripheral blood B cells in rheumatoid arthritis. Scand J Immunol. 2004 Jul-Aug;60(1-2):209-18.
Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC., University College London, London, UK. g.cambridge(at)ucl.ac.uk: Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006 Mar;54(3):723-32
Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. , University College London, Center for Rheumatology, London, UK. maria.leandro(at)ucl.ac.uk: Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006 Feb;54(2):613-20
Panayi GS, Hainsworth JD, Looney RJ, Keystone EC., Department of Rheumatology, Guy's, King's and St Thomas' Medical School, Guy's Hospital, St Thomas' Street, London SE1 9RT, UK. gabriel.panayi(at)kcl.ac.uk: Panel discussion on B cells and rituximab: mechanistic aspects, efficacy and safety in rheumatoid arthritis and non-Hodgkin's lymphoma. Rheumatology (Oxford). 2005 May;44 Suppl 2:ii18-ii20
Dörner T., Charite University Hospital Berlin and the Deutsches Rheumaforschungszentrum, Berlin, Germany. thomas.dorner(at)charite.de: Crossroads of B cell activation in autoimmunity: rationale of targeting B cells. J Rheumatol Suppl. 2006 May;77:3-11.
Pescovitz MD., Department of Surgery, Indiana University, Indianapolis, IN, USA. mpescov(at)iupui.edu: Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant. 2006 May;6(5 Pt 1):859-66